Loading...
Book a Meeting

Ribosomal Marker Antibody Development Service

Introduction Workflow Core Applications Why us FAQs

Are you currently facing challenges in elucidating complex cellular pathways, struggling with inconsistent antibody performance for ribosomal targets, or needing highly specific tools to investigate ribosome-related diseases? Our ribosomal marker antibody development services help you obtain highly specific and rigorously validated antibodies, enabling a deeper understanding of ribosome function and pathology through our advanced antigen design, robust immunization strategies, and comprehensive antibody characterization.

Introduction of Ribosomal Marker Antibody Development Services

Ribosomes, the cell's protein synthesis machinery, are complex ribonucleoprotein particles composed of ribosomal RNA (rRNA) and numerous ribosomal proteins. Beyond their canonical role, ribosomal proteins are increasingly recognized for their extra-ribosomal functions and as critical indicators of cellular stress, ribosome biogenesis status, and disease states like cancer (often termed 'ribosomopathies'). Developing specific antibodies against these ribosomal markers is crucial for dissecting ribosome assembly, function, regulation, and their involvement in pathology, thereby paving the way for novel diagnostic and therapeutic strategies.

A simplified diagram illustrates that Rpl5 knockdown disrupts the expression of eye - specific markers and impedes the evagination of the eye vesicle. (OA Literature)Fig.1 Rpl5 knockdown interferes with eye-specific marker expression and eye vesicle evagination.1

Our Streamlined Workflow

Our process is designed for transparency and efficiency, ensuring you receive high-quality antibodies suited to your specific research needs.

  • Antigen Design and Preparation (2-4 weeks)
    In-depth bioinformatic analysis of the target ribosomal protein to identify optimal immunogenic regions, considering protein structure, conservation, and potential cross-reactivity. Synthesis of peptide antigens or expression and purification of recombinant protein antigens.
  • Immunization and Hybridoma Development or Antiserum Collection (8-16 weeks)
    Development of robust immunization protocols tailored to the antigen and host species. For monoclonals: hybridoma generation, screening, and cloning. For polyclonals: primary and booster immunizations, serum collection, and titer monitoring.
  • Antibody Purification and Initial Characterization (1-2 weeks)
    Purification of antibodies from antiserum or hybridoma supernatant using appropriate chromatography techniques (e.g., Protein A/G, antigen-specific affinity purification). Initial characterization by ELISA to confirm reactivity against the target antigen.
  • Comprehensive Validation (1-3 weeks)
    Rigorous validation of antibody specificity and performance in client-specified applications (e.g., Western Blotting with appropriate cell lysates or tissue samples, IHC on relevant tissue sections, IF, IP).
  • Final Deliverables and Reporting
    Preparation of a comprehensive project report, antibody aliquoting, and shipment.

Core Applications

Antibodies targeting ribosomal markers are versatile tools with a wide range of applications in biological and biomedical research. Their ability to specifically identify and quantify ribosomal proteins or their modified forms allows researchers to delve into various aspects of cellular function and disease.

  • WB

To detect and quantify the expression levels of specific ribosomal proteins in cell lysates or tissue homogenates, and to study changes in their abundance or post-translational modifications in response to various stimuli or disease states.

  • IHC

For visualizing the localization and expression patterns of ribosomal proteins within tissue sections. This is crucial for understanding tissue-specific ribosome characteristics and identifying alterations in diseases, such as cancer, where ribosome biogenesis is often upregulated.

  • IF / ICC

To determine the subcellular localization of ribosomal proteins within cells (e.g., cytoplasm, nucleolus, association with specific organelles) and to observe changes in their distribution during different cellular processes or under stress conditions.

  • ELISA

For quantitative measurement of ribosomal protein levels in biological fluids or cell extracts, useful for biomarker discovery and validation.

  • IP / Co-IP

To isolate specific ribosomal proteins and their interacting partners, thereby elucidating ribosomal complex composition and identifying novel regulatory interactions or extra-ribosomal functions.

  • Flow Cytometry

To analyze the expression of ribosomal proteins on a per-cell basis, which can be useful for studying heterogeneous cell populations or identifying cells with altered ribosome content.

Why Choose Creative Biolabs?

  • Expertise-Driven Partnership

Choosing Creative Biolabs means collaborating with a team deeply rooted in ribosome biology, committed to translating scientific rigor into research success through tailored antibody development.

  • Optimized Antigen Design

Our meticulous antigen design ensures maximal immunogenicity while eliminating cross-reactivity, crafting ribosomal markers with precision for superior antibody performance.

  • Cutting-Edge Validation

Leveraging advanced technologies and multi-platform validation, we guarantee antibodies that deliver consistent, application-specific results, critical for reproducible ribosomal research.

  • Proven Excellence in Research

Supported by published collaborations, our custom antibodies reflect a history of reliability and innovation, making Creative Biolabs a trusted name in advancing ribosomal discoveries.

FAQs

Q: What type of antigen do you recommend for developing antibodies against ribosomal proteins?

A: It depends on your specific target and application! For many ribosomal proteins, highly immunogenic peptide antigens designed from unique regions can yield excellent results. However, for detecting conformational epitopes or for certain applications, full-length recombinant proteins might be more suitable.

Q: Can Creative Biolabs develop antibodies that recognize specific post-translational modifications (PTMs) on ribosomal proteins?

A: Absolutely! We have extensive experience in developing PTM-specific antibodies, including those for phosphorylated or ubiquitinated ribosomal proteins. This requires careful antigen design and rigorous screening, which our team is well-equipped to handle. Let's talk about the specific modification you're interested in!

Q: How do you ensure the specificity of the ribosomal marker antibodies you develop?

A: Specificity is paramount. We employ a multi-tiered approach including careful antigen design to avoid conserved regions, screening against related proteins, and thorough validation using appropriate controls, such as knockout/knockdown cell lysates or tissues, and testing across recommended applications.

Q: What if I need antibodies for a newly identified ribosomal protein with little known information?

A: That's a challenge we embrace! Our bioinformatics team excels at analyzing novel sequences to predict immunogenic regions and design effective antigens. We can guide you through the process, leveraging our experience to maximize the chances of success even for poorly characterized targets.

Q: How does your custom ribosomal antibody service compare to purchasing off-the-shelf antibodies?

A: While off-the-shelf antibodies can be convenient, they may not always offer the specificity, affinity, or application suitability you need, especially for less common ribosomal markers or specific epitopes. Our custom service provides antibodies tailored precisely to your target and your experimental requirements, often leading to more reliable and publishable data.

Ready to discuss your project or learn more about how our ribosomal marker antibody development services can benefit your research? Our expert team is here to help.

Reference

  1. Schreiner, Corinna, et al. "The ribosomal protein L5 functions during xenopus anterior development through apoptotic pathways." Frontiers in Cell and Developmental Biology 10 (2022): 777121. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only. We do not provide direct services or products for patients.
Online Inquiry
For Research Use Only. We do not provide direct services or products for patients.
Contact Us

(USA)
(UK)
(Germany)

Inquiry